Ru-Vert®, a combination product, containing in each tablet, 25 mg of pentylenetetrazol, 12.5 mg of pheniramine maleate, and 50 mg of nicotinic acid, was evaluated in the treatment of seventeen patients with benign paroxysmal positional vertigo. The study was double-blind with crossover. Ru-Vert® at a dosage of two tablets t.i.d. was found to reduce significantly the nystagmus and the vertigo induced by Hallpike maneuvers in these patients.
Get full access to this article
View all access options for this article.
References
1.
BaranyR: Zur Klinik und Theorie des Eisenbahn-Nystagmus. Acta Otolaryngol2: 260–265, 1922.
2.
DixMRHallpikeCS: Symptomatology and diagnosis of certain common disorders of the vestibular system. Proc R Soc Med45: 341–354, 1952.
HarrisonM: Benign positional vertigo, in WolfsonRJ (ed): The Vestibular System and Its Diseases.Philadelphia, University of Pennsylvania Press, 1966.
5.
HerndonJWHaugO: Clinical experience with electronystagmography. South Med J59: 1146–1150, 1966.
6.
PouJWQuinnHJ: A doubleblind placebo controlled study of Ru-Vert® in patients with vertigo. Curr Ther Res9: 558–562, 1967.
7.
WalkerHMLevJ: Statistical Inference.New York, Henry Holt and Co., 1953.
8.
RümkeLChrdeJongeH: Design statistical analysis and interpretation, in LaurenceDRBacharachAL (eds): Evaluation of Drug Activitiess Pharmacometrics.London, Academic Press, 1964.
